Yarrow Bioscience Inc YARW

$18.03 -1.60 (-8.15%)

Valuation

Market cap
48,135,000
Revenue TTM
$570,000
Net income TTM
$-26,480,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-4,645.61%
Debt to equity
0.00

Trading

Volume
99,100
Avg volume
169,020
Day's range
$17.99 – $19.86
Shares out
2,670,000
Stochastic %K
75%
Beta
2.10
Analysts
Moderate Buy
Price target
$59.00

Price

Company profile

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Website
https://www.yarrowbioscience.com
Address
40 10 th Avenue, Floor 7, New York, United States

Latest news

No headlines yet.